ustekinumab and vedolizumab dual biologic therapy in the treatment of crohn’s disease
Clicks: 90
ID: 188000
2017
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
26.7
/100
90 views
19 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #242 of 309 articles by views in Frontiers in pharmacology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 309 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
We present a case of refractory ileocolonic Crohn’s disease in a 27-year-old female treated with dual ustekinumab and vedolizumab biologic therapy. She had mucosal healing for the first time in 13 years after a 10-month treatment of ustekinumab overlapped with 6 months of vedolizumab. No side effects were observed during the 6 months of dual biologic therapy. Short-term dual biologic therapy may be considered as a treatment option for induction of remission in refractory cases of Crohn’s disease.
| Reference Key |
liu2017caseustekinumab
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Eddie Y. Liu;Dustin E. Loomes |
| Journal | Frontiers in pharmacology |
| Year | 2017 |
| DOI |
10.1155/2017/5264216
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.